Cigna’s CEO is buying big — and Wall Street is paying attention. With earnings up, a pharmacy-benefit shake-up underway, and valuations looking healthy, CI might just be the quiet value stock investors have been waiting for. Let’s break it down — and have fun doing it. 😎💊📈

Read entire article

Booz Allen just flashed insider conviction: CEO Horacio Rozanski purchased ~$2M of BAH stock. Despite near-term revenue pressure from funding delays, the firm sports a record backlog, mission-critical AI/cyber programs, and steady capital returns. We unpack the bull/bear, valuation, and what could flip the narrative from pause to play.

Read entire article

FTI Consulting just posted record EPS while its tri-titled chief bought $1.13M of stock and the board added $500M to buybacks. A cycle-balanced franchise that compounds through booms, busts, and boardroom “oh-no’s.”

Read entire article

CEO buy signal, steady margins, and intermodal momentum—yet top line is flat-ish and valuation looks fair. Our fun + smart breakdown with TL;DR & FAQs.

Read entire article

Insiders and institutions are revving up for CarMax’s comeback — even as used car sales slow and margins tighten. With shares 70% below their peak and a major digital overhaul underway, this could be the turnaround ride of the year. 🚘📉 Or just another trip to the mechanic.

Read entire article

AngioDynamics insiders bought low and doubled up, while Wall Street funds practically own the company. With MedTech sales surging and earnings around the corner, can $ANGO climb higher — or will tariffs and volatility zap the gains?

Read entire article

RH stock has crashed, but its CEO is still buying, funds are backing, and Paris is shining. With shorts circling and debt looming, is RH a comeback story—or just a fancy couch with shaky legs?

Read entire article